Introduction {#Sec1}
============

Primary palmar hyperhidrosis can cause occupational, social, and emotional problems that affect physical and mental well-being and usually lead to diminished quality of life \[[@CR1]\]. Two of the treatment options currently considered as being most effective for this condition are periodical local injections of botulinum toxin and endoscopic thoracic sympathectomy (ETS) \[[@CR2], [@CR3]\]. At present, there are no guidelines for the clinical use of these treatment modalities for palmar hyperhidrosis. In most cases, botulinum toxin and ETS are contemplated only when the less invasive medical treatments, such as topical or systemic medications (including glycopyrrolate and clonidine) and iontophoresis, have failed to provide adequate control of hyperhidrosis \[[@CR4]--[@CR8]\].

Studies directly comparing the effectiveness of botulinum toxin and ETS for palmar hyperhidrosis are scarce \[[@CR9]\]. Recently, our group has observed that ETS is superior to botulinum toxin in the treatment of palmar hyperhidrosis in terms of efficacy and patient satisfaction, particularly in subjects with baseline severe palmar hyperhidrosis \[[@CR10]\]. However, as yet there are no published studies that analyze the economic impact of both treatments. We believe that such an analysis is necessary, particularly because of the high cost associated with both treatments. Regardless of perspective, the objective of such an evaluation would be to provide information on the clinical and economic consequences related to these therapeutic alternatives faced by patient/physician. From an economic standpoint, an outcomes analysis may provide general evidence that could guide future research efforts by identifying decision-critical parameters that help to indicate the best way to treat palmar hyperhidrosis.

Therefore, the aim of this study was to evaluate the cost (expressed in monetary terms), with regard to efficiency and patient-reported outcomes, between botulinum toxin and ETS in the treatment of palmar hyperhidrosis in a real-world scenario.

Materials and Methods {#Sec2}
=====================

Population and Design {#Sec3}
---------------------

Following a retrospective and observational design, an economic evaluation was performed comparing the cost-efficacy of botulinum toxin versus ETS in palmar hyperhidrosis. Candidates were consecutive patients with idiopathic palmar hyperhidrosis treated with either one of these two techniques between January 2005 and December 2010 in the Department of Dermatology and Thoracic Surgery of the Reina Sofia University Hospital (Córdoba, Spain).

Our hospital protocols for these treatments were followed in all cases. Prior to treatment with botulinum toxin, patients underwent nerve block anesthesia of the median, radial, and ulnar nerves with 0.5% bupivacaine injected into the wrist. Botulinum toxin A (Botox Cosmetic^®^, Allergan Pharmaceuticals, Westport, Ireland), 100 IU, was diluted in 5 mL of 0.9% saline. Guided by a 1-cm^2^ grid drawn on a transparent dressing (Tegaderm^®^, 3M Health Care, Neuss, Germany) covering the palm, 0.1 mL/grid cell was injected using a 30-G needle, avoiding the thenar eminence; 0.1 mL was injected into each phalanx, except the first phalanx of the thumb, which was left free of toxin. A total of 100 IU of botulinum toxin was injected into each hand.

Endoscopic thoracic sympathectomy was performed in all cases under general anesthesia with double lumen intubation. The patient was placed in the semi-prone, anti-Trendelenburg position. The material was inserted through two openings, one located in the fourth intercostal space in the mid-axillary line and the other in the third space before the axillary line. The sympathetic chain was interrupted, with an endoscopic diathermy hook, at different levels depending on the location of the hyperhidrosis (exclusively palmar or mixed) (Table [1](#Tab1){ref-type="table"}). In each case, we cauterized the ganglion over the neck of the rib with coagulation diathermy from the superior edge of the rib to just above the inferior edge. The patient was kept under observation in the ambulatory major surgery unit, and was discharged on the same day if no postoperative complications occurred. All patients were informed of the risks and side effects and gave their written informed consent before treatment.Table 1Levels of resection of the sympathetic chainResectionLevelsTotalPalmar (CH)Palmar + axilar (CH)Including T2T22 (1.5%)2 (0)2 (2)T2T313 (10.3%)16 (16)8 (6)T2T432 (25.4%)34 (30)26 (2)Total4752 (46)36 (10)Including T3T318 (14.3%)30 (24)2 (2)T3T426 (20.6%)21 (2)24 (6)T3T56 (4.7%)4 (2)6 (6)Total5055 (28)32 (14)No data29 (23.2%)17 (16)12 (10)*CH* compensatory hyperhidrosis

Data Source {#Sec4}
-----------

Socio-demographic and clinical information about patients was collected from computerized medical records and a telephone survey. The survey contained questions about the baseline situation (family medical history and locations of compensatory hyperhidrosis and its severity) and post-treatment situation (hyperhidrosis severity, patient satisfaction, and associated side effects). The cost considered for botulinum toxin was the manufacturer's selling price stated in the Spanish Catalogue of Pharmaceutical Specialties plus VAT \[[@CR6]\] (Table [2](#Tab2){ref-type="table"}). Unit costs per ETS and stay costs for a 4-hour-a-day hospital admission were obtained from the Reina Sofia University Hospital's economic management database.

Evaluation of Effectiveness and Patient Satisfaction {#Sec5}
----------------------------------------------------

Effectiveness was evaluated by estimating hyperhidrosis severity at baseline and after treatment using the Hyperhidrosis Disease Severity Scale (HDSS) \[[@CR11]\]. The patient is asked to select the statement that best reflects his or her experience with sweating of the specified body area (Table [3](#Tab3){ref-type="table"}). Next to each statement, there is a number that indicates how responses should be scored. This validated scale offers a quick and easy subjective way to measure the severity of hyperhidrosis according to how it affects daily life. A score of 1 or 2 indicates mild-to-moderate hyperhidrosis, and 3 or 4 severe hyperhidrosis. Post-treatment, as part of a subjective efficacy evaluation and patient satisfaction, the HDSS is administered again. An improvement of 1 or 2 points on the HDSS scale represents a reduction in sweat production of 50% or 80%, respectively. Unlike gravimetric methods of measuring sweat production, it is easy to use, making it ideal for use with telephone surveys. Absolute pre-treatment HDSS (HDSSpre), post-treatment HDSS (HDSSpost), and incremental effectiveness (HDSSdif) were evaluated. Patient satisfaction was measured on a continuous numerical scale from 0 to 10, with 0 representing "totally dissatisfied" and 10 "totally satisfied".Table 2Sources for valuation of unit costs associated with botulinum toxin and endoscopic thoracic sympathectomyCost hour^−1^ (€)Time (h)Cost session^−1^ (€)ETSOperating room^a^453.131453.13 Thoracic surgeon286.671286.67 Anesthetist237.041237.04 Ambulatory major surgery unit103.251.5154.88 Total----1,131.72Botulinum toxin Drug (PTR + VAT)140.662281.32 Operating room^a^453.140.5226.57 Dermatologist152.200.576.10 Total----583.99*ETS* endoscopic thoracic sympathectomy; *PTR* price to retailer^a^Fungible and nursery cost are included

Cost-Effectiveness Analysis {#Sec6}
---------------------------

A responder was defined as a patient who reported at least a two-degree improvement on the HDSS scale with respect to the baseline value. Both absolute and incremental effectiveness were determined for both modalities of treatment. Incremental cost per additional responder (ICER) following botulinum toxin compared to ETS was calculated. In addition, the annual per-patient cost/HDSSdif ratio and cost/satisfaction ratio were calculated. A descriptive temporal analysis for each year over a 5-year period for these parameters was performed. Analyses included only direct costs (drug and health resources). Since the maximum number of sessions with botulinum toxin per year was two and the ratio between the costs of ETS and one toxin session was close to two, we established 1 year as the time horizon for the economic analysis. The study was conducted from the perspective of the Spanish National Health System. All costs are shown in Euros (€) and updated to June 2011.

Statistical Analysis {#Sec7}
--------------------

The normality of the data was assessed using the Shapiro--Wilk test; logarithmic transformation was used when variables did not have a normal distribution. To check for differences between the two treatment groups, the Chi-square test was used for qualitative variables and the Student's *t* test for quantitative variables. All the data presented in the text, tables, and graphs are expressed as mean and standard deviation (SD), unless otherwise specified. We considered a 95% confidence interval for the mean and a *P* value of less than 0.05 as statistically significant. All tests were performed with different packages of the R statistical programming environment (GNU) \[[@CR12]\].

All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation and with the Declaration of Helsinki of 1975. Informed consent was obtained from all the patients included in the study.

Results {#Sec8}
=======

Baseline Characteristics of the Study Groups {#Sec9}
--------------------------------------------

Of a total of 345 candidates, only 228 patients were included for subsequent analysis---161 women and 67 men aged 28.2 ± 10.3 years---since no information could be obtained from the other patients by telephone survey. When efficacy and patient satisfaction were assessed, an average of 3.69 years had elapsed since treatment. Analysis of the differences between the two treatments (Table [4](#Tab4){ref-type="table"}) revealed that the severity of hyperhidrosis was greater (*P* = 0.0017) in patients undergoing ETS (*n* = 128) compared to those who opted for botulinum toxin (*n* = 100). Nonetheless, efficacy (*P* \< 0.001) and patient satisfaction (*P* \< 0.001) were greater after endoscopic surgery. No significant differences were observed for the other variables analyzed.Table 3Hiperhidrosis Disease Severity Scale (HDSS) score system"How would you rate the severity of your hyperhidrosis?"ScoreMy sweating is never noticeable and never interferes with my daily activities1My sweating is tolerable but sometimes interferes with my daily activities2My sweating is barely tolerable and frequently interferes with my daily activities3My sweating is intolerable and always interferes with my daily activities4

Descriptive Temporal Analysis {#Sec10}
-----------------------------

The temporal analysis of efficacy, satisfaction, security, and costs by year over the first 5 years of use of both treatments in our hospital is shown in Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"}, and Fig. [1](#Tab1){ref-type="table"}. Efficacy and satisfaction increased progressively after the first year of treatment in both groups. Dropouts in the botulinum toxin group appeared mainly during the first year, generally due to lack/loss of efficacy or to adverse effects, in most cases transitory and associated with the technique.Table 4Descriptive analysis of the study group of patients with palmar hyperhidrosis treated with either botulinum toxin or endoscopic thoracic sympathectomyBotulinum toxin (*n* = 100)Sympathectomy (*n* = 128)*P*Gender (men/women)26/7441/87n.s.^a^Age (years)27.7 (12--55)28.8 (13--56)n.s.^a^Family medical history39 (39%)52 (40.6%)n.s.^a^HDSSpre3.48 (2--4)3.73 (2--4)0.0017^b^HDSSpost1.71 (1--4)1.12 (1--3)\<0.001^b^Patient satisfaction6.66 (2.81)8.16 (2.60)\<0.001^b^*HDSSpost* HDSS post-treatment, *HDSSpre* HDSS pre-treatment, *n.s*. non significant^a^Chi-square analysis with Yates' correction^b^Kruskall--Wallis testTable 5Descriptive temporal analysis for the treatment of palmar hyperhidrosis with botulinum toxinDuration of treatment (years)1 *n* = 662 *n* = 183 *n* = 104 *n* = 45 *n* = 2Gender (men/women)19/472/162/82/21/1Age (years)29 ± 1026 ± 1123 ± 525 ± 1017 ± 1HDDSpre3.41 ± 0.633.56 ± 0.513.60 ± 0.523.75 ± 0.504.00 ± 0.00HDDSpost1.83 ± 0.971.50 ± 0.621.60 ± 0.841.00 ± 0.101.50 ± 0.71HDDSdif^a^1.58 ± 1.022.06 ± 0.542.00 ± 0.672.75 ± 0.502.50 ± 0.71Satisfaction6.1 ± 3.17.3 ± 2.18.4 ± 0.88.7 ± 1.510.0 ± 0.0Adverse events3814841 Transitory/permanent34/414/08/04/01/0 Weakness3114740 Paresthesias21010 Hematoma20000 Pain90101Dropouts366010 Hyperhidrosis cessation10000 Lack/loss efficacy234000 Adverse events51010 Others71000Total cost (€)77,08821,02411,6804,6722,336Cost year^−1^ patient^−1^ (€)1,1681,1681,1681,1681,168Cost HDSSdif^−1^ (€)701.4 ± 153.1616.4 ± 106.8661.8 ± 139.2438.2 ± 48.6486.6 ± 68.8Cost satisfaction^−1^ (€)578.8 ± 252.4476.8 ± 149.4353.6 ± 17.5343.4 ± 21.2294.4 ± 0.00*HDSSpre* HDSS pre-treatment; *HDSSpost* HDSS post-treatment^a^HDSSdif = \[HDSSpost − HDSSpre\]

When both modalities of treatment are compared by considering annual per-patient value of cost/HDSSdif and cost/satisfaction ratios, ETS yields lower values than botulinum toxin for both ratios during the first year. As of this moment, an overlapping effect is observed between ETS cost/HDSSdif ratio and botulinum toxin cost/satisfaction ratio (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Temporal analysis of cost/HDSS and cost/satisfaction ratios comparing botulinum toxin versus endoscopic thoracic sympathectomy for the treatment of palmar hyperhidrosis

Incremental Cost-effectiveness Analysis {#Sec11}
---------------------------------------

In the course of the 5-year study period, total costs associated with palmar hyperhidrosis treatment at Reina Sofia University Hospital were € 178,704.00 for botulinum toxin and € 144,896.00 for ETS (Tables [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}). There are statistically significant differences in the reduction of HDSS and degree of satisfaction when botulinum toxin is compared with ETS (all *P* \< 0.05) (Table [4](#Tab4){ref-type="table"}). The incremental cost per additional responder following treatment with botulinum toxin was € 125 higher than after ETS during the first year (Table [7](#Tab7){ref-type="table"}). As the number-needed-to-treat (NNT) value shows, four patients have to be treated with botulinum toxin to obtain the same rate of effectiveness that is achieved with ETS (Table [8](#Tab8){ref-type="table"}).Table 6Descriptive temporal analysis for the treatment of palmar hyperhidrosis with endoscopic thoracic sympathectomyDuration of treatment (years)1 *n* = 942 *n* = 183 *n* = 104 *n* = 45 *n* = 2Gender (men/women)31/637/112/80/41/1Age (years)28 ± 933 ± 1032 ± 1217 ± 120 ± 3HDDSpre3.71 ± 0.543.78 ± 0.433.70 ± 0.483.75 ± 0.504.00 ± 0.00HDDSpost1.11 ± 0.371.28 ± 0.571.00 ± 0.001.00 ± 0.001.00 ± 0.00HDDSdif^a^2.61 ± 0.692.50 ± 0.712.70 ± 0.482.75 ± 0.503.00 ± 0.00Satisfaction8.1 ± 2.68.2 ± 2.78.5 ± 2.28.5 ± 1.310.0 ± 0.0Adverse events80181042 Compensatory hyperhidrosis77181042 Transitory pain85110 Permanent pain30000 Neurapraxia40000 Others80010Total cost (€)106,40820,37611,3204,5282,264Cost year^−1^ patient^−1^ (€)1,1321,1321,1321,1321,132Cost HDSSdif^−1^ (€)461.3 ± 179.9513.5 ± 240.4433.9 ± 91.1424.4 ± 94.3377.3 ± 0.0Cost satisfaction^−1^ (€)163.2 ± 154.5209.4 ± 253.2146.8 ± 59.1135.5 ± 20.9113.2 ± 0.0*HDSSpost* HDSS post-treatment; *HDSSpre* HDSS pre-treatment^a^HDSSdif = \[HDSSpost − HDSSpre\]Table 7Incremental cost-effectiveness ratio of botulinum toxin versus endoscopic thoracic sympathectomy for the treatment of palmar hyperhidrosisComparative treatment modalitiesIncremental cost (€)Incremental effectivenessICER (€)^a^Botulinum toxin (A) vs. ETS (B)30.260.24125.00*ICER* Incremental cost-effectiveness ratio^a^ICER = (total cost~A~ − total cost~B~)/(effectiveness~B~ − effectiveness~A~)Table 8Cost analysis of the treatment with botulinum toxin or endoscopic thoracic sympathectomy for palmar hyperhidrosisTreatment*n*HDSSdif \> 2^a^OddsORARRRRRNNTBotulinum toxin100680.68 \[0.58, 0.76\]1----ETS1281190.92 \[0.87, 0.96\]6.22 \[2.80, 13.80\]−0.25 \[−0.35, −0.14\]−0.36 \[−0.57, −0.18\]−4 \[−3, −7\]*ARR* absolute risk reduction; *ETS* endoscopic thoracic sympathectomy; *HDSSpost* HDSS post-treatment; *HDSSpre* HDSS pre-treatment; *NNT* number-needed-to-treat; *OR* Odds ratio; *RRR* relative risk reduction^a^HDSSdif = \[HDSSpost − HDSSpre\]

Discussion {#Sec12}
==========

In our study, ETS for palmar hyperhidrosis appears to be more effective and less costly than botulinum toxin during the first year of treatment. Botulinum toxin was associated with higher total costs and less effectiveness than ETS in a 5-year palmar hyperhidrosis treatment program in our hospital. When cost/HDSSdif and cost/satisfaction ratios are evaluated over 5 years, ETS-associated cost/satisfaction and botulinum toxin-associated cost/HDSSdif were the lower and the higher values, respectively. Cost/HDSSdif and cost/satisfaction ratios represent how much money, on average, is required to improve one unit of HDSS or to increase one level in the satisfaction scale, respectively, per patient and year, for each modality of treatment. Hence, we may conclude that increasing the satisfaction of these patients by ETS is the cheapest strategy, and that the most expensive approach is to reduce sweating severity by means of botulinum toxin injections. Considering that four patients have to be treated with botulinum toxin to obtain the same rate of effectiveness that is achieved with ETS, and that the ICER for botulinum toxin was € 125, this gives a potential saving of € 3,125 if ETS had been chosen by all patients. This saving accounts for 2.93% of the ETS-associated total cost during the first year of the study.

One of the benefits of using real-world data is that they can provide estimates of long-term effectiveness in a variety of typical practice settings when multiple alternative interventions or clinical strategies are compared in a diverse study population, which reflects the range and distribution of patients observed in clinical practice \[[@CR13]\]. This reinforces the applicability of our results to similar populations as it reduces uncertainty in the clinical practice decision-making process when estimates of pharmacoeconomic studies relying on clinical trial data are used.

However, various aspects related to the study design should be taken into account when evaluating the results. Thus, the single-center retrospective design used may have detracted from the representativeness of the results through the effect of inaccuracies in the patients' clinical histories and telephone survey. This potential bias, inherent in most retrospective work, is a result of the lack of well-defined standards for visit recording and of clinical practice variability---two distinct features of clinical trial designs. In any event, our results could be validated by a future standardized, multi-center, prospective study. Secondly, the initial and final measurement of the severity of hyperhidrosis was made retrospectively, thus raising the possibility of a recall bias. However, since hyperhidrosis is a lengthy process with an evolutionary period of over 10 years in most cases, we believe that patients recall the effects produced by palmar hyperhidrosis before and after they underwent treatment with sufficient precision.

One other potential shortcoming of our study was excluding costs arising from the management of adverse reactions associated with each treatment. A treatment may be more expensive, but by being more effective or involving less complications/sequelae, it may be preferable for the patient. We consider necessary that patient should take into account this vital information when choosing one of these therapeutic options. In the group of patients treated with ETS, both patient satisfaction and efficacy were clearly conditioned by the occurrence of compensatory hyperhidrosis (CH). CH is the most common side effect of ETS, as well as the most disabling side effect when it is severe \[[@CR14]\]. The fact that the efficacy of this procedure is conditioned by the severity of CH, when the two measures should be independent, helps to explain the impact of this side effect on subjects who undergo surgery. These patients would probably be willing to accept this side effect if it were offset by a significant improvement in palmar hyperhidrosis. This could explain why greater satisfaction is seen in this group despite the higher incidence of CH after ETS. The frequency of the rest of the adverse reactions, such as pain, weakness, or hematoma was minor, mostly transitory, and with difficult-to-estimate derived costs.

In summary, our data suggest that when considering therapeutic options for palmar hyperhidrosis, ETS may offer greater efficacy, greater patient satisfaction, and lower direct cost than botulinum toxin. In the virtual absence of similar economic studies, this study can be used as an additional source of information for placing both options within the scope of the Spanish National Health System.
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